Key Takeaways A phase 2b trial gave 148 adults aged 70 to 85 one infusion of donated mesenchymal stem cells or placebo. At nine months, the 200 million cell group walked 63.4 meters farther than placebo. The six-month gap of 41.3 meters did not reach statistical significance. A second open-label
Key Takeaways A new randomized trial tested injecting mesenchymal stem cells into the spinal fluid of 18 people with progressive MS. The trial’s main measure of nerve repair did not improve. The result was not statistically significant. Some secondary signals looked promising at six months but faded by twelve months.
Key Takeaways A new human trial injected lab-grown heart muscle cells into 20 patients with advanced heart failure during bypass surgery. Patients who received the cells walked further, showed better heart blood flow, and had thicker heart muscle than those who had surgery alone. Pumping strength, scar size, and quality
